Proficio Capital Partners LLC Acquires Shares of 17,406 Vericel Co. (NASDAQ:VCEL)

Proficio Capital Partners LLC bought a new position in Vericel Co. (NASDAQ:VCEL - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,406 shares of the biotechnology company's stock, valued at approximately $956,000.

Other institutional investors have also recently made changes to their positions in the company. Arcadia Investment Management Corp MI purchased a new position in Vericel in the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC raised its stake in shares of Vericel by 511.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock worth $70,000 after purchasing an additional 1,058 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Vericel by 826.6% during the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock valued at $138,000 after purchasing an additional 2,240 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Vericel during the third quarter valued at $146,000. Finally, KBC Group NV boosted its position in shares of Vericel by 82.5% during the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock valued at $149,000 after buying an additional 1,224 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Stephens restated an "overweight" rating and set a $65.00 price objective on shares of Vericel in a research report on Wednesday, January 15th. BTIG Research lifted their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Canaccord Genuity Group increased their price target on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Finally, Truist Financial reaffirmed a "buy" rating and issued a $61.00 price objective (down previously from $67.00) on shares of Vericel in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Vericel presently has an average rating of "Moderate Buy" and a consensus target price of $62.29.

Remove Ads

Vericel Trading Up 0.0 %

Vericel stock traded up $0.02 during trading on Tuesday, reaching $47.96. The company had a trading volume of 346,495 shares, compared to its average volume of 374,022. The firm's 50-day simple moving average is $54.16 and its 200 day simple moving average is $51.73. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 799.47 and a beta of 1.78.

Insider Transactions at Vericel

In other Vericel news, insider Jonathan Siegal sold 3,908 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total transaction of $242,256.92. Following the sale, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. This trade represents a 76.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the transaction, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,092 shares of company stock valued at $1,683,582 over the last quarter. 5.20% of the stock is currently owned by company insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.